Implementing well-being in the management of psoriasis: An expert recommendation.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
08
02
2023
accepted:
30
08
2023
pubmed:
12
10
2023
medline:
12
10
2023
entrez:
11
10
2023
Statut:
aheadofprint
Résumé
Psoriasis causes detriment in a person's physical, mental and social health which impairs their quality of life (QoL). However, the current psoriasis management may not adequately address all relevant health domains. Since the goal of healthcare is to restore or maintain health, health outcomes should include all areas of the patient's overall health. Life satisfaction, QoL and patient well-being are essential to a comprehensive approach to the disease. With the inclusion of more people-centred policies, care of patients with psoriasis should evolve towards a holistic and integrated assessment of the disease impact, including subjective measures of well-being in order to encompass all aspects of health. The main objective of this expert review is to give the concept of well-being a place as an entity within the holistic therapeutic approach for patients with psoriasis. Identifying and defining common goals beyond the skin with the patient and testing them throughout the course of treatment will benefit and enhance treatment success. We propose a series of recommendations for application in clinical practice, providing tangible clinical guidance for implementing well-being in the management of psoriasis. Among the recommendations are the need to initially listen to the patient, to know their level of empowerment or what they want to achieve, their preferences in decision making, the evaluation of not only the physical but also the emotional impact of the disease (well-being), the definition of the aspects that can generate a cumulative deterioration of the disease throughout life, and a continuous assessment of the patient's preferences with the opinion of the expert clinician and the integration of the knowledge of external clinical evidence.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Almirall R&D, Barcelona, Spain
Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301-1315.
Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-ii23.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
GPA. Global psoriasis atlas. [cited 2022 Oct 31]. Available from: https://www.globalpsoriasisatlas.org/en/
Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PCM, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155:729-736.
Griffiths CEM, Jo S-J, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179:173-181.
Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156:1245-1250.
Demma A, Suitner C, Ferruzza E, Nicolini C, Donini M. The indirect effect of a focus group for psoriatic patients on their caregivers. Res Psychother. 2021;24:486.
Trettin B, Feldman S, Andersen F, Danbjørg DB, Agerskov H. Improving management of psoriasis patients receiving biological treatment: a qualitative approach. Nurs Open. 2021;8:1283-1291.
Mrowietz U, Sümbül M, Gerdes S. Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation. J Eur Acad Dermatol Venereol. 2023;37:1731-1738.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984-991.
Lesner K, Reich A, Szepietowski JC, Dalgard FJ, Gieler U, Tomas-Aragones L, et al. Determinants of psychosocial health in psoriatic patients: a multi-national study. Acta Derm Venereol. 2017;97:1182-1188.
Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183:548-558.
WHO. Global report on psoriasis. Geneva: World Health Organization; 2016. [cited 2022 Mar 8]. Available from: https://apps.who.int/iris/handle/10665/204417
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989-1004.
A67_R9-en.pdf. [cited 2022 Dec 20]. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R9-en.pdf
WHO. Primary health care. [cited 2022 May 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/primary-health-care
NEJM Catalyst. What is patient-centered care? NEJM Catalyst; 2017 [cited 2022 Mar 16]. Available from: https://catalyst.nejm.org/doi/full/10.1056/CAT.17.0559
Cunningham BA, Marsteller JA, Romano MJ, Carson KA, Noronha GJ, McGuire MJ, et al. Perceptions of health system orientation: quality, patient centeredness, and cultural competency. Med Care Res Rev. 2014;71:559-579.
McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, et al. Patient-centered approaches to health care: a systematic review of randomized controlled trials. Med Care Res Rev. 2013;70:567-596.
Rathert C, Wyrwich MD, Boren SA. Patient-centered care and outcomes: a systematic review of the literature. Med Care Res Rev. 2013;70:351-379.
Saha S, Beach MC, Cooper LA. Patient centeredness, cultural competence and healthcare quality. J Natl Med Assoc. 2008;100:1275-1285.
Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, et al. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol. 2015;72:345-348.
Koetsier MIA, van de Kerkhof PCM. “Patient-centered treatment” for mild-to-moderate psoriasis. J Dermatolog Treat. 2015;26:1-6.
Okland TS, Armstrong AW. Patient-centered outcomes in dermatology. Curr Dermatol Rep. 2015;4:15-19.
Augustin M, Mrowietz U, Luck-Sikorski C, von Kiedrowski R, Schlette S, Radtke MA, et al. Translating the WHA resolution in a member state: towards a German programme on ‘destigmatization’ for individuals with visible chronic skin diseases. J Eur Acad Dermatol Venereol. 2019;33:2202-2208.
Luck-Sikorski C, Roßmann P, Topp J, Augustin M, Sommer R, Weinberger NA. Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient-reported outcome measures. J Eur Acad Dermatol Venereol. 2022;36:499-525.
Sommer R, Weinberger N-A, von Spreckelsen R, von Spreckelsen R, Mrowietz U, Schielein MC, et al. A structured intervention for medical students significantly improves awareness of stigmatisation in visible chronic skin diseases: a randomised controlled trial. Acta Derm Venereol. 2022;102:adv00641.
Weinberger N-A, Mrowietz S, Luck-Sikorski C, von Spreckelsen R, John SM, Sommer R, et al. Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: results of a controlled trial in future educators. Health Expect. 2021;24:1790-1800.
Blome C, Augustin M, Behechtnejad J, Rustenbach SJ. Dimensions of patient needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res. 2011;303:11-17.
Maul J-T, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33:700-708.
da Silva N, Augustin M, Langenbruch A, Mrowietz U, Reich K, Thaçi D, et al. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. Eur J Dermatol. 2020;30:267-278.
da Silva N, von Stülpnagel C, Langenbruch A, Danckworth A, Augustin M, Sommer R. Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults. J Eur Acad Dermatol Venereol. 2020;34:1010-1018.
da Silva N, Augustin M, Langenbruch A, Mrowietz U, Reich K, Thaçi D, et al. Sex-related impairment and patient needs/benefits in anogenital psoriasis: difficult-to-communicate topics and their impact on patient-centred care. PLoS One. 2020;15:e0235091.
Armstrong A, Edson-Heredia E, Zhu B, Burge R, Bell S, Crowley JJ, et al. Treatment goals for psoriasis as measured by patient benefit index: results of a National Psoriasis Foundation survey. Adv Ther. 2022;39:2657-2667.
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185:1146-1159.
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185:323-334.
Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28:488-491.
Augustin M, Radtke M. Health economic issues in psoriasis. Expert Rev Dermatol. 2008;3:S19-S23.
Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish Nationwide study. Acta Derm Venereol. 2019;99:1224-1230.
Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122:602-607.
Kirsten N, Rustenbach S, von Kiedrowski R, Sorbe C, Reich K, Augustin M. Which PASI outcome is most relevant to the patients in real-world care? Life (Basel). 2021;11:1151.
Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9:5-18.
Read C, Armstrong AW. Association between the mental health of patients with psoriasis and their satisfaction with physicians. JAMA Dermatol. 2020;156:754-762.
Schuster B, Ziehfreund S, Albrecht H, Spinner CD, Biedermann T, Peifer C, et al. Happiness in dermatology: a holistic evaluation of the mental burden of skin diseases. J Eur Acad Dermatol Venereol. 2020;34:1331-1339.
Schuster B, Peifer C, Ziehfreund S, Tizek L, Biedermann T, Zink A, et al. Happiness and depression in psoriasis: a cross-sectional study in Germany. Qual Life Res. 2022;31:1761-1773.
Wiking M, Iversen L, Cernica C, Birkjaer M, Okkels C, Meyer-Christensen E, et al. The psoriasis happiness study: people with self-reported psoriasis have a significantly reduced emotional well-being and a large happiness gap compared with fellow citizens. J Am Acad Dermatol. 2018;79:AB291.
Red Española para el Desarrollo Sostenible. Informe Mundial de la Felicidad 2022. Red Española para el Desarrollo Sostenible 2022. [cited 2022 Jul 11]. Available from: https://reds-sdsn.es/publicacion-informe-mundial-de-la-felicidad-2022
Ruggeri K, Garcia-Garzon E, Maguire Á, Matz S, Huppert FA. Well-being is more than happiness and life satisfaction: a multidimensional analysis of 21 countries. Health Qual Life Outcomes. 2020;18:192.
The Health & Happiness Research Foundation. World psoriasis happiness report 2018. 2018 [cited 2022 Mar 8]. Available from: https://psoriasishappiness.report/
Callahan D. The WHO definition of “health”. Stud Hastings Cent. 1973;1:77-88.
Huber M, Knottnerus JA, Green L, Horst H, Jadad AR, Kromhout D, et al. How should we define health? BMJ. 2011;343:d4163.
Ryff CD. Happiness is everything, or is it? Explorations on the meaning of psychological well-being. J Pers Soc Psychol. 1989;57:1069-1081.
Mills IJ. A person-centred approach to holistic assessment. Prim Dent J. 2017;6:18-23.
WHO. Mental health: strengthening our response. 2022 [cited 2022 Mar 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/mental-health-strengthening-our-response
CDC. Well-being concepts: HRQOL. 2018 [cited 2022 May 12]. Available from: https://www.cdc.gov/hrqol/wellbeing.htm
van Ee I, Deprez E, Egeberg A, Augustin M, Conrad C, Corazza V, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022;36:403-412.
Linton M-J, Dieppe P, Medina-Lara A. Review of 99 self-report measures for assessing well-being in adults: exploring dimensions of well-being and developments over time. BMJ Open. 2016;6:e010641.
Supranowicz P, Paź M. Holistic measurement of well-being: psychometric properties of the physical, mental and social well-being scale (PMSW-21) for adults. Rocz Panstw Zakl Hig. 2014;65:251-258.
Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84:167-176.
WHO. International classification of impairments, disabilities, and handicaps: a manual of classification relating to the consequences of disease, published in accordance with resolution WHA29.35 of the Twenty-ninth World Health Assembly, May 1976. World Health Organization; 1980 [cited 2022 Jun 22]. Available from: https://apps.who.int/iris/handle/10665/41003
Sommer R, Westphal L, Mrowietz U, Gerdes S, Augustin M. Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire. J Eur Acad Dermatol Venereol. 2022;36:e986-e987.
Liu L, Li S, Zhao Y, Zhang J, Chen G. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China. Qual Life Res. 2018;27:1323-1333.
Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7:481-488.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012;132:76-84.
Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33:123-127.
Pattinson R, Trialonis-Suthakharan N, Gupta S, Henry AL, Lavallée JF, Otten M, et al. Patient-reported outcome measures in dermatology: a systematic review. Acta Derm Venereol. 2021;101:adv00559.
Haeck I m, ten Berge O, van Velsen SGA, de Bruin-Weller MS, Bruijnzeel-Koomen CAFM, Knol MJ. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2012;26:236-241.
Kitchen H, Cordingley L, Young H, Griffiths CEM, Bundy C. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol. 2015;172:1210-1221.
McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CEM, et al. Development of the PSORIQoL, a psoriasis- specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149:323-331.
Gupta M, Gupta A. The psoriasis life stress inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240-243.
Inanır I, Aydemir Ö, Gündüz K, Esen Danacı A, Türel A. Developing a quality of life instrument in patients with psoriasis: the psoriasis quality of life questionnaire (PQLQ). Int J Dermatol. 2006;45:234-238.
Dauden E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Caloto MT, et al. Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual Life Outcomes. 2012;10:56.
Lewis VJ, Finlay AY. Two decades experience of the psoriasis disability index. Dermatology. 2005;210:261-268.
Schuster B, Ziehfreund S, Schielein MC, Tizek L, Biedermann T, Peifer C, et al. Adding happiness to complement the dermatology quality of life index in psoriasis and atopic dermatitis healthcare: a cross-sectional study. Eur J Dermatol. 2022;32:220-226.
WHO. People-centred health care: a policy framework. 2013 [cited 2022 Mar 31]. Available from: https://www.who.int/publications-detail-redirect/9789290613176
Betteridge N, Boehncke W-H, Bundy C, Gossec L, Gratacós J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol. 2016;30:576-585.
Mold J. Goal-directed health care: redefining health and health care in the era of value-based care. Cureus. 2017;9:e1043.
Prignano F, Brunasso AMG, Fabbrocini G, Argenziano G, Bardazzi F, Borroni RG, et al. Sharing patient and clinician experiences of moderate-to-severe psoriasis: a nationwide Italian survey and expert opinion to explore barriers impacting upon patient wellbeing. J Clin Med. 2022;11:2801.
International Labour Organization. Social code - Book V - statutory health insurance. 1988 [cited 2022 Apr 1]. Available from: https://www.ilo.org/dyn/natlex/natlex4.detail?p_isn=43202
Agencia Estatal Boletín Oficial del Estado. Ley 33/2011, de 4 de octubre, General de Salud Pública. «BOE» núm 240, de 05/10/2011; 2011:36.
LEAP. Law 23 December 1978, n. 833 Establishment of the Department of Public Health | UNEP Law and Environment Assistance Platform. 1978 [cited 2022 Apr 1]. Available from: https://leap.unep.org/countries/it/national-legislation/law-23-december-1978-n-833-establishment-department-public-health
GOV.UK. Health and Social Care Act 2012: fact sheets. GOV.UK; 2012 [cited 2022 Apr 1]. Available from: https://www.gov.uk/government/publications/health-and-social-care-act-2012-fact-sheets
Hart D. Das Patientenrechtegesetz 2013. Forum. 2019;34:452-457.
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70:871-881.e1-30.
Chico LE. Personality dimensions and subjective well-being. Span J Psychol. 2006;9:38-44.
Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment goals in psoriasis: which outcomes matter most? Am J Clin Dermatol. 2020;21:505-511.
Scholl I, Zill JM, Härter M, Dirmaier J. An integrative model of patient-centeredness - a systematic review and concept analysis. PLoS One. 2014;9:e107828.
Bieber C, Müller KG, Blumenstiel K, Hochlehnert A, Wilke S, Hartmann M, et al. A shared decision-making communication training program for physicians treating fibromyalgia patients: effects of a randomized controlled trial. J Psychosom Res. 2008;64:13-20.
Deinzer A, Babel H, Veelken R, Kohnen R, Schmieder RE. Shared decision-making with hypertensive patients. Results of an implementation in Germany. Dtsch Med Wochenschr. 2006;131:2592-2596.
Khoury LR, Skov L, Møller T. Facing the dilemma of patient-centred psoriasis care: a qualitative study identifying patient needs in dermatological outpatient clinics. Br J Dermatol. 2017;177:436-444.
Dressler C, Lambert J, Grine L, Galdas P, Paul C, Zidane M, et al. Therapeutic patient education and self-management support for patients with psoriasis - a systematic review. J Dtsch Dermatol Ges. 2019;17:685-695.
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, et al. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study). BMJ Open. 2023;13:e060536.
Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51:1087-1110.
New A, Tsianakas A, von Martial S, Sommer R, Blome C. How important is subjective well-being for patients? A qualitative interview study of people with psoriasis. Qual Life Res. 2022;31:3355-3363.
Blome C, von Stülpnagel CC, Augustin M, Mrowietz U, Reich K, Muehlan H, et al. Measuring patient-relevant benefits in psoriasis with the patient benefit index: development and preliminary validation of a 10-item short form. Br J Dermatol. 2022;187:588-589.
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727-1736.
Cochrane Germany. Resources evidence-based medicine and health care. [cited 2022 May 12]. Available from: https://www.cochrane.de/Ressourcen-EBM
von Stülpnagel CC, Augustin M, Düpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review. J Eur Acad Dermatol Venereol. 2021;35:2166-2184.
Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol. 2013;44:74-81.